{"id":"etesevimab","rwe":[],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"COVID-19","category":"indication"},{"label":"Eli Lilly and Company","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":679.676,"date":"","count":266,"signal":"Infusion related reaction","source":"DrugCentral FAERS","actionTaken":"Reported 266 times (LLR=680)"},{"llr":365.619,"date":"","count":126,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 126 times (LLR=366)"},{"llr":277.401,"date":"","count":77,"signal":"COVID-19 pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 77 times (LLR=277)"},{"llr":249.487,"date":"","count":107,"signal":"Chest discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=249)"},{"llr":224.216,"date":"","count":191,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 191 times (LLR=224)"},{"llr":100.177,"date":"","count":57,"signal":"Oxygen saturation decreased","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=100)"},{"llr":88.904,"date":"","count":74,"signal":"Back pain","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=89)"},{"llr":72.436,"date":"","count":34,"signal":"Acute respiratory failure","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=72)"},{"llr":61.417,"date":"","count":57,"signal":"Chest pain","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=61)"},{"llr":60.953,"date":"","count":44,"signal":"Hyperhidrosis","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=61)"}],"commonSideEffects":[],"specialPopulations":{"Pregnancy":"There are insufficient data to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Bamlanivimab and etesevimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.","Geriatric use":"Of the 1141 patients receiving bamlanivimab and etesevimab in BLAZE-1, 30% were 65 years of age and older and 10% were 75 years of age and older. Based on population PK analyses, there is no difference in PK of bamlanivimab or etesevimab in geriatric patients compared to younger patients.","Paediatric use":"Bamlanivimab and etesevimab administered together are authorized for the treatment of mild to moderate COVID-19 and post-exposure prophylaxis for prevention of COVID-19 in pediatric patients, including neonates."}},"trials":[],"aliases":[],"company":"Eli Lilly and Company","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ETESEVIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:29:24.156907+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:29:32.185583+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETESEVIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:29:32.986521+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:33.560305+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650488/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:33.455678+00:00"}},"allNames":"ly-cov016","offLabel":[],"synonyms":["etesevimab","LY-CoV016","LY3832479","JS016","CB6","NP005"],"timeline":[{"date":"2020-11-09","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eli Lilly and Company)"}],"aiSummary":"Ly-Cov016 (Etesevimab) is a small molecule developed by Eli Lilly and Company, approved by the FDA in 2020 for the treatment of COVID-19. It is a monoclonal antibody that targets the SARS-CoV-2 virus, preventing it from entering host cells. Etesevimab is patented and commercially available, with no generic manufacturers listed. Key safety considerations include potential allergic reactions and infusion-related side effects. As a monoclonal antibody, it is designed to provide targeted therapy.","approvals":[{"date":"2020-11-09","orphan":false,"company":"Eli Lilly and Company","regulator":"FDA"}],"brandName":"Ly-Cov016","ecosystem":[{"indication":"COVID-19","otherDrugs":[{"name":"bamlanivimab","slug":"bamlanivimab","company":"Eli Lilly and Company"},{"name":"casirivimab","slug":"casirivimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"imdevimab","slug":"imdevimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"nirmatrelvir","slug":"nirmatrelvir","company":"Pfizer, Inc."}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Etesevimab is a monoclonal antibody that binds to the SARS-CoV-2 spike protein, specifically to the receptor-binding domain (RBD), preventing the virus from interacting with the host cell's angiotensin-converting enzyme 2 (ACE2) receptor."},"commercial":{"launchDate":"2020","_launchSource":"DrugCentral (FDA 2020-11-09, Eli Lilly and Company)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5454","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ETESEVIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETESEVIMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:06:01.594430","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:35.325718+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bamlanivimab","drugSlug":"bamlanivimab","fdaApproval":"2020-11-11","relationship":"same-target"},{"drugName":"casirivimab","drugSlug":"casirivimab","fdaApproval":"2020-11-21","relationship":"same-target"},{"drugName":"chloroquine","drugSlug":"chloroquine","fdaApproval":"1949-10-31","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"clioquinol","drugSlug":"clioquinol","fdaApproval":"","relationship":"same-target"},{"drugName":"clofazimine","drugSlug":"clofazimine","fdaApproval":"1986-12-15","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"heparin","drugSlug":"heparin","fdaApproval":"1939-02-09","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"imdevimab","drugSlug":"imdevimab","fdaApproval":"2020-11-21","relationship":"same-target"}],"genericName":"etesevimab","indications":{"approved":[{"name":"COVID-19","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"bamlanivimab","brandName":"bamlanivimab","genericName":"bamlanivimab","approvalYear":"2020","relationship":"same-target"},{"drugId":"casirivimab","brandName":"casirivimab","genericName":"casirivimab","approvalYear":"2020","relationship":"same-target"},{"drugId":"chloroquine","brandName":"chloroquine","genericName":"chloroquine","approvalYear":"1949","relationship":"same-target"},{"drugId":"clioquinol","brandName":"clioquinol","genericName":"clioquinol","approvalYear":"","relationship":"same-target"},{"drugId":"clofazimine","brandName":"clofazimine","genericName":"clofazimine","approvalYear":"1986","relationship":"same-target"},{"drugId":"heparin","brandName":"heparin","genericName":"heparin","approvalYear":"1939","relationship":"same-target"},{"drugId":"imdevimab","brandName":"imdevimab","genericName":"imdevimab","approvalYear":"2020","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04885452","phase":"","title":"Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-09-21","conditions":["SARS-CoV Infection","Covid19"],"enrollment":756,"completionDate":"2023-12-18"},{"nctId":"NCT05268601","phase":"","title":"COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-10-14","conditions":["COVID-19"],"enrollment":251,"completionDate":"2023-12-22"},{"nctId":"NCT04427501","phase":"PHASE2,PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-17","conditions":["COVID-19"],"enrollment":3307,"completionDate":"2023-02-21"},{"nctId":"NCT05167279","phase":"PHASE1","title":"A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-12-16","conditions":["COVID-19"],"enrollment":48,"completionDate":"2022-12-08"},{"nctId":"NCT04790786","phase":"PHASE4","title":"UPMC OPTIMISE-C19 Trial, a COVID-19 Study","status":"TERMINATED","sponsor":"Erin McCreary","startDate":"2021-03-10","conditions":["Covid19"],"enrollment":4571,"completionDate":"2022-06-16"},{"nctId":"NCT05205759","phase":"PHASE3","title":"Non-inferiority Trial on Monoclonal Antibodies in COVID-19","status":"TERMINATED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-12-09","conditions":["COVID-19"],"enrollment":319,"completionDate":"2022-04-05"},{"nctId":"NCT05439044","phase":"","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-01","conditions":["Immunocompromised Patients"],"enrollment":4000,"completionDate":"2022-12-31"},{"nctId":"NCT04634409","phase":"PHASE2","title":"A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-29","conditions":["COVID-19"],"enrollment":1755,"completionDate":"2021-10-18"},{"nctId":"NCT04497987","phase":"PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-02","conditions":["COVID-19","SARS-CoV2"],"enrollment":1180,"completionDate":"2021-05-20"},{"nctId":"NCT04441931","phase":"PHASE1","title":"A Study of LY3832479 (LY-CoV016) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-19","conditions":["Healthy"],"enrollment":26,"completionDate":"2020-10-02"},{"nctId":"NCT04611789","phase":"PHASE1","title":"A Study of LY3832479 (LY-CoV016) in Healthy Participants 1","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-02","conditions":["Healthy"],"enrollment":18,"completionDate":"2021-02-10"},{"nctId":"NCT04931238","phase":"PHASE2","title":"Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01-20","conditions":["COVID-19","SARS-CoV-2"],"enrollment":200,"completionDate":"2022-12-31"},{"nctId":"NCT04441918","phase":"PHASE1","title":"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-06-05","conditions":["COVID-19; and High Infection Risk of SARS-CoV-2"],"enrollment":40,"completionDate":"2020-12-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Etesevimab"}]},"crossReferences":{"MMSL":"343519","NDDF":"018633","UNII":"N7Q9NLF11I","VANDF":"4040109","INN_ID":"11873","RXNORM":"2477854","UMLSCUI":"C5421804","chemblId":"CHEMBL4650488","ChEMBL_ID":"CHEMBL4650488","KEGG_DRUG":"D11944","DRUGBANK_ID":"DB15897","PUBCHEM_CID":"44468170","IUPHAR_LIGAND_ID":"11331","MESH_SUPPLEMENTAL_RECORD_UI":"C000711968"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Eli Lilly","relationship":"Original Developer"}],"publicationCount":146,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"Eli Lilly and Company","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Monoclonal antibody","firstApprovalDate":"2020","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-09T00:00:00.000Z","mah":"Eli Lilly and Company","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:35.325718+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}